cagrilintide semaglutide combination cagrisema phase 3 2025 results The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies We are all anxiously awaiting
Description
If successful, these compounds would bring the higher efficacy of dual-agonist therapy (demonstrated by tirzepatide) into an oral format
AAV2, adeno-associated viral type-2
This would require daily or multiple daily injections impractical for patients and physicians
This conservative approach has merit because it keeps a higher dose in reserve as a strategic tool
